Gestational diabetes mellitus affects about 6 to 9 percent of US pregnancies, which means more than 200,000 cases every year. It also links to outcomes that often surprise people, from a roughly 1.7 times higher risk of preeclampsia to a big jump in newborn hypoglycemia. Let’s look at the key statistics that shape diagnosis, treatment, and what happens after delivery.
Key Takeaways
- GDM increases risk of preeclampsia by 1.5-2.0 fold (OR 1.7, 95% CI 1.5-2.0)
- Macrosomia (birthweight >4000g) occurs in 15-45% of GDM pregnancies vs 8-12% general
- Neonatal hypoglycemia (<2.6 mmol/L) risk 50% higher in GDM offspring (OR 1.49)
- The one-step 75g oral glucose tolerance test (OGTT) at 24-28 weeks diagnoses GDM if fasting plasma glucose ≥5.1 mmol/L
- Carpenter-Coustan criteria for 100g OGTT: 2-hour value ≥6.67 mmol/L or fasting ≥5.27 mmol/L indicates GDM
- IADPSG criteria using 75g OGTT: any one elevated value (fasting ≥5.1, 1h ≥10.0, 2h ≥8.5 mmol/L) diagnoses GDM
- Nutrition therapy alone normalizes glycemia in 70-85% mild GDM cases within 1-2 weeks
- Insulin therapy recommended if fasting >5.3 mmol/L or 1h postprandial >7.8 mmol/L persists
- Metformin crosses placenta but reduces insulin needs by 30-50% with neonatal safety
- In the United States, gestational diabetes mellitus (GDM) affects approximately 6-9% of all pregnancies, translating to over 200,000 cases annually
- Globally, the prevalence of GDM has risen sharply, with estimates indicating 14-18% of pregnancies worldwide affected based on IADPSG criteria
- Among Hispanic women in the US, the prevalence of GDM is about 13.1%, the highest among major ethnic groups
- Maternal obesity (BMI ≥30 kg/m²) increases GDM risk by 3- to 7-fold compared to normal weight women
- Previous history of GDM confers a 30-84% risk of recurrence in subsequent pregnancies
- Family history of diabetes (first-degree relative) raises GDM odds ratio to 2.71 (95% CI 2.27-3.23)
Gestational diabetes affects 6 to 9 percent of pregnancies and sharply raises risks for mother and baby.
Related reading
01 · Category
Complications And Outcomes30 stats
01
GDM increases risk of preeclampsia by 1.5-2.0 fold (OR 1.7, 95% CI 1.5-2.0)
02
Macrosomia (birthweight >4000g) occurs in 15-45% of GDM pregnancies vs 8-12% general
03
Neonatal hypoglycemia (<2.6 mmol/L) risk 50% higher in GDM offspring (OR 1.49)
04
Women with GDM have 7.4-fold increased risk of type 2 diabetes within 5-10 years
05
Offspring of GDM mothers have 2-fold risk of childhood obesity by age 5-7
06
Shoulder dystocia incidence 2-3 times higher in GDM (OR 2.34, 95% CI 1.68-3.26)
07
Cesarean delivery rate 20-50% higher in GDM (OR 1.16-1.78 depending on control)
08
Preterm birth (<37 weeks) OR 1.38 (95% CI 1.27-1.50) in GDM pregnancies
09
Neonatal respiratory distress syndrome risk increased OR 2.38 in uncontrolled GDM
10
Postpartum hemorrhage risk OR 1.64 (95% CI 1.06-2.55) in GDM with insulin
11
Offspring adiposity at birth increased by 139g per 5 mmol/L higher maternal glucose
12
Progression to T2DM: 5.7% per year in first 5 years post-GDM
13
Polycythemia (hematocrit >65%) in 10% GDM neonates vs 3% controls
14
Maternal hypertension risk OR 2.1 in GDM vs non-GDM
15
Childhood impaired glucose tolerance OR 2.2 at age 10-14 in GDM exposed
16
Stillbirth risk elevated after 39 weeks in uncontrolled GDM (1-2 per 1000)
17
Hyperbilirubinemia requiring phototherapy OR 1.4 in GDM neonates
18
50g oral glucose tolerance test abnormal in 50-60% post-GDM at 6 weeks
19
Operative vaginal delivery OR 1.3 higher in GDM due to macrosomia
20
Offspring T2DM risk OR 8.4 by adulthood in GDM mothers with obesity
21
Polyhydramnios incidence 5-10% in GDM vs 1% general population
22
NICU admission OR 1.43 (95% CI 1.20-1.70) for GDM infants
23
Maternal weight retention >5kg at 1 year post-GDM OR 2.5 for T2DM
24
Congenital anomalies not increased if GDM diagnosed after first trimester
25
Preeclampsia after 20 weeks OR 2.65 in GDM with vascular risk factors
26
Offspring metabolic syndrome OR 1.58 at age 6-11 years
27
Intrauterine fetal demise risk 4-fold higher if polyhydramnios present
28
Breastfeeding reduces maternal T2DM risk by 9% per year duration post-GDM
29
Neonatal hypocalcemia OR 1.8 in infants of insulin-treated GDM mothers
30
Long-term offspring hypertension risk increased OR 1.81 in adolescence
Interpretation
Complications And Outcomes Interpretation
In the Complications and Outcomes category, gestational diabetes substantially worsens pregnancy and long term health risks, with outcomes like preeclampsia up 1.7 fold, shoulder dystocia rising to 2 to 3 times higher, and a 7.4 fold increase in women developing type 2 diabetes within 5 to 10 years.
02 · Category
Diagnosis And Screening27 stats
01
The one-step 75g oral glucose tolerance test (OGTT) at 24-28 weeks diagnoses GDM if fasting plasma glucose ≥5.1 mmol/L
02
Carpenter-Coustan criteria for 100g OGTT: 2-hour value ≥6.67 mmol/L or fasting ≥5.27 mmol/L indicates GDM
03
IADPSG criteria using 75g OGTT: any one elevated value (fasting ≥5.1, 1h ≥10.0, 2h ≥8.5 mmol/L) diagnoses GDM
04
Universal screening recommended at 24-28 weeks gestation by ADA, with earlier screening for high-risk women
05
HbA1c ≥5.7% (39 mmol/mol) alone insufficient for GDM diagnosis but useful for risk stratification
06
Fasting plasma glucose ≥5.1 mmol/L at 24-28 weeks detects 46% of GDM cases per HAPO study
07
Two-step approach: 50g glucose challenge test (GCT) non-fasting ≥7.8 mmol/L proceeds to 100g OGTT
08
Sensitivity of two-hour 75g OGTT is 90% for detecting GDM vs 75% for two-step method
09
First-trimester fasting glucose ≥5.1 mmol/L predicts 20-30% GDM risk, warranting early screening
10
Random plasma glucose ≥11.1 mmol/L with symptoms can diagnose overt diabetes in pregnancy
11
Glycated albumin (GA) >15.5% at 24 weeks has AUC 0.82 for GDM prediction
12
Ultrasound estimated fetal weight >90th percentile prompts GDM screening before 24 weeks
13
DIPSI test (single 75g glucose post-prandial ≥7.8 mmol/L after 2h) 93% sensitive in India
14
Continuous glucose monitoring (CGM) metrics: time above range >140 mg/dL >15% indicates poor control
15
WHO recommends 75g OGTT for all pregnant women in high-prevalence settings
16
ACOG prefers two-step screening with 130 mg/dL (7.2 mmol/L) GCT cutoff for 88% sensitivity
17
Fructosamine levels >286 μmol/L at 24-28 weeks OR 4.5 for GDM diagnosis
18
Home OGTT with capillary glucose calibrated to plasma equivalents acceptable per NICE guidelines
19
Positive urine glucose on two occasions without glucosuria explanation warrants OGTT
20
Early GDM screening (<20 weeks) for BMI >30 yields 50% case detection rate
21
1-hour 50g GCT ≥140 mg/dL (7.8 mmol/L) has 85% sensitivity, 81% specificity for GDM
22
Postpartum OGTT at 4-12 weeks: fasting ≥5.1 or 2h ≥7.8 mmol/L diagnoses prediabetes/diabetes
23
Risk score calculators (e.g., HAPO risk score) with AUC 0.75 for GDM prediction
24
Fasting capillary glucose ≥5.3 mmol/L at booking detects 66% GDM cases early
25
75g OGTT 2h value ≥8.5 mmol/L alone detects 40% GDM with lowest adverse outcomes
26
HbA1c 5.7-6.4% combined with risk factors prompts early OGTT per ADA
27
Selective screening misses 16.7% GDM cases vs universal's 100% detection
Interpretation
Diagnosis And Screening Interpretation
In the Diagnosis and Screening category, universal testing at 24 to 28 weeks using a 75 g or 100 g OGTT catches gestational diabetes with threshold-based criteria, and in the HAPO study a fasting plasma glucose of at least 5.1 mmol/L detected about 46% of cases, showing why standard screening is essential even before all cases are identified.
03 · Category
Management And Treatment27 stats
01
Nutrition therapy alone normalizes glycemia in 70-85% mild GDM cases within 1-2 weeks
02
Insulin therapy recommended if fasting >5.3 mmol/L or 1h postprandial >7.8 mmol/L persists
03
Metformin crosses placenta but reduces insulin needs by 30-50% with neonatal safety
04
Target fasting glucose <5.3 mmol/L, 1h postprandial <7.8 mmol/L, 2h <6.7 mmol/L per ADA
05
Moderate exercise (30 min/day, 5 days/week) lowers fasting glucose by 0.5-1.0 mmol/L
06
Glyburide less favored due to 4x higher neonatal hypoglycemia vs insulin (11.7% vs 2.4%)
07
Self-monitoring of blood glucose (SMBG) 4-7 times/day correlates with 20% better glycemic control
08
Low glycemic index diet (<55) reduces insulin initiation by 25% vs standard diet
09
Myo-inositol 2g twice daily reduces GDM incidence by 65.9% in high-risk women
10
Probiotics (Lactobacillus rhamnosus) lower fasting glucose by 0.32 mmol/L in meta-analysis
11
CGM use improves time-in-range by 10% vs SMBG in GDM
12
Weekly antenatal visits with fetal ultrasound reduce adverse outcomes by 15%
13
Bedtime snack (protein+complex carb) reduces nocturnal hypoglycemia by 40%
14
Rapid-acting insulin analogs (aspart/lispro) equal human insulin in safety/efficacy
15
DPP-4 inhibitors not recommended due to fetal malformation risks in animal studies
16
Resistance training 2-3x/week improves insulin sensitivity by 20-30%
17
Calorie restriction to 25-35 kcal/kg ideal body weight for obese GDM
18
Telemedicine SMBG review reduces HbA1c by 0.4% vs standard care
19
Vitamin D supplementation 1000 IU/day lowers fasting glucose 0.25 mmol/L
20
Induction at 39 weeks for diet-controlled GDM reduces macrosomia by 50%
21
Glargine insulin safe with no increased congenital anomalies vs NPH
22
Mindfulness-based stress reduction lowers postprandial glucose spikes by 1.2 mmol/L
23
Combined aerobic+resistance exercise 150 min/week OR 0.52 for insulin need
24
Omega-3 fatty acids 1000 mg/day reduce inflammation markers in GDM
25
SMBG targets: premeal 3.9-5.3 mmol/L optimal for neonatal outcomes
26
Magnesium oxide 250 mg/day improves insulin sensitivity OR 0.65
27
Timing of insulin: preprandial for fasting control, postprandial correction doses
Interpretation
Management And Treatment Interpretation
For managing and treating gestational diabetes, most mild cases can normalize with nutrition therapy alone in 1 to 2 weeks and insulin is then added when fasting exceeds 5.3 mmol/L or 1 hour postprandial exceeds 7.8 mmol/L, while metformin can cut insulin needs by 30 to 50% as it crosses the placenta.
More related reading
04 · Category
Prevalence And Incidence30 stats
01
In the United States, gestational diabetes mellitus (GDM) affects approximately 6-9% of all pregnancies, translating to over 200,000 cases annually
02
Globally, the prevalence of GDM has risen sharply, with estimates indicating 14-18% of pregnancies worldwide affected based on IADPSG criteria
03
Among Hispanic women in the US, the prevalence of GDM is about 13.1%, the highest among major ethnic groups
04
In Australia, GDM prevalence increased from 4.0% in 2012 to 7.3% in 2018 using updated diagnostic criteria
05
In India, GDM affects up to 41.9% of pregnant women in urban areas according to HAPO study follow-up data
06
In the UK, GDM incidence rose from 2.1% in 2007 to 3.8% in 2017, linked to rising maternal obesity
07
Among Asian American women, GDM prevalence is 10.9%, compared to 5.7% in non-Hispanic whites
08
In Sweden, GDM prevalence is 1.6-2.3% with selective screening, but rises to 5.5% with universal screening
09
In Brazil, GDM affects 7.6% of pregnancies, with higher rates in the Northeast region at 9.2%
10
In China, the pooled prevalence of GDM is 14.8% (95% CI: 12.9-16.9%) from 2006-2016 studies
11
In South Africa, GDM prevalence among black women is 8.6%, higher than 4.2% in whites
12
In Canada, GDM rates increased from 3.9% in 2003-2004 to 6.6% in 2012-2013
13
In Japan, GDM prevalence is approximately 12-15% using IADPSG criteria
14
In Mexico, GDM affects 12.5% of pregnancies, with urban rates at 18.6%
15
In Europe overall, GDM prevalence varies from 5-20% depending on diagnostic criteria used
16
In the US, from 2016-2019, GDM prevalence was 8.41% among deliveries, up from 6.02% in 2007-2014
17
In urban India, GDM prevalence reached 17.8% in a 2019 multicenter study of 6000 women
18
In Saudi Arabia, GDM prevalence is 24.2% among pregnant women screened universally
19
In New Zealand, Maori women have GDM prevalence of 10.2% vs 5.1% in Europeans
20
In Iran, pooled GDM prevalence is 11.9% (95% CI 9.3-14.8%) from meta-analysis
21
In Turkey, GDM incidence is 7.8% with two-step screening approach
22
In Poland, GDM prevalence increased to 9.7% in 2018 from 4.8% in 2010
23
In Singapore, GDM affects 13.4% of pregnancies, highest in Indian ethnicity at 17.1%
24
In Egypt, GDM prevalence is 22.8% in urban areas per DIPSi study adaptation
25
In Russia, GDM rates are 4.5-6.2% with Carpenter-Coustan criteria
26
In Thailand, GDM prevalence is 12.1% using IADPSG thresholds
27
In the Netherlands, GDM incidence is 0.8-1.2% with selective screening
28
In Chile, GDM affects 23.4% of high-risk pregnancies screened
29
In the US Native American population, GDM prevalence is 10.9%
30
In France, GDM prevalence is 17.7% with universal IADPSG screening
Interpretation
Prevalence And Incidence Interpretation
Across countries, gestational diabetes is becoming more common, rising from about 4.0% in Australia in 2012 to 7.3% in 2018 and from 2.1% in the UK in 2007 to 3.8% in 2017, showing an increasing prevalence and incidence trend that aligns with the higher estimates seen globally, including 14 to 18% of pregnancies worldwide.
05 · Category
Risk Factors29 stats
01
Maternal obesity (BMI ≥30 kg/m²) increases GDM risk by 3- to 7-fold compared to normal weight women
02
Previous history of GDM confers a 30-84% risk of recurrence in subsequent pregnancies
03
Family history of diabetes (first-degree relative) raises GDM odds ratio to 2.71 (95% CI 2.27-3.23)
04
Advanced maternal age (>35 years) is associated with 2.3 times higher GDM risk vs <25 years
05
South Asian ethnicity increases GDM risk with OR 2.49 (95% CI 1.82-3.41) compared to whites
06
Polycystic ovary syndrome (PCOS) elevates GDM risk by 3.44-fold (95% CI 2.44-4.84)
07
Multiple pregnancy (twins+) has OR 2.2 for GDM compared to singleton
08
Excessive gestational weight gain (>0.5 kg/week in second/third trimester) OR 1.82 for GDM
09
Hispanic ethnicity carries OR 1.77 (95% CI 1.46-2.15) for GDM vs non-Hispanic white
10
African American women have 1.5-fold higher GDM risk than white women
11
Short stature (<1.55m) associated with OR 1.52 (95% CI 1.11-2.09) for GDM
12
Prior macrosomia (>4000g) increases GDM risk OR 2.18 (95% CI 1.75-2.72)
13
Smoking during pregnancy slightly reduces GDM risk OR 0.78 (95% CI 0.70-0.87)
14
Low socioeconomic status correlates with OR 1.4 for GDM in urban settings
15
High parity (≥5 births) OR 1.92 (95% CI 1.36-2.71) for GDM
16
Vitamin D deficiency (<50 nmol/L) increases GDM risk OR 1.64 (95% CI 1.08-2.49)
17
Iron supplementation >30 mg/day raises GDM OR 1.70 (95% CI 1.14-2.52)
18
Assisted reproductive technology pregnancies have OR 1.6-2.0 for GDM
19
High pre-pregnancy HbA1c (>5.7%) OR 3.5 for GDM development
20
Sedentary lifestyle pre-pregnancy OR 1.45 (95% CI 1.12-1.88) for GDM
21
High dietary glycemic load (>140 g/day) increases GDM risk OR 2.06
22
Native American ethnicity OR 1.9 for GDM vs whites
23
Sleep duration <6 hours/night OR 1.82 (95% CI 1.42-2.34) for GDM
24
Antidepressant use (SSRIs) OR 1.41 (95% CI 1.16-1.73) associated with GDM
25
High caffeine intake (>200 mg/day) OR 1.47 for GDM risk
26
Chronic hypertension pre-pregnancy OR 2.14 (95% CI 1.82-2.52)
27
BMI 25-29.9 kg/m² OR 1.97 vs normal BMI for GDM
28
History of neonatal hypoglycemia in prior child OR 1.65
29
Glycosylated hemoglobin ≥5.7% at first prenatal visit OR 7.2 for GDM
Interpretation
Risk Factors Interpretation
Among the key risk factors for gestational diabetes, maternal obesity stands out as the strongest signal with a 3 to 7 fold increase in risk, and this is reinforced by other high risk profiles such as PCOS at 3.44 fold and advanced age over 35 years at 2.3 times higher risk.
report visual · Key figures
Rising Prevalence of Gestational Diabetes (GDM)
Across countries, reported GDM prevalence/incidence has increased over recent years, suggesting a growing public health burden.
4%
In Australia, GDM prevalence increased from 4.0% in 2012 to 7.3% in 2018 using updated diagnostic criteria
2.1%
In the UK, GDM incidence rose from 2.1% in 2007 to 3.8% in 2017, linked to rising maternal obesity
3.9%
In Canada, GDM rates increased from 3.9% in 2003-2004 to 6.6% in 2012-2013
8.41%
In the US, from 2016-2019, GDM prevalence was 8.41% among deliveries, up from 6.02% in 2007-2014
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Gestational Diabetes Statistics. Gitnux. https://gitnux.org/gestational-diabetes-statistics
MLA
Min-ji Park. "Gestational Diabetes Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/gestational-diabetes-statistics.
Chicago
Min-ji Park. 2026. "Gestational Diabetes Statistics." Gitnux. https://gitnux.org/gestational-diabetes-statistics.
Sources & references
28 datasets cited across this report · attribution is report-level